Get started
ALTERITY THERAPEUTICS LIMITEDALTERITY THERAPEUTICS LIMITEDALTERITY THERAPEUTICS LIMITED

ALTERITY THERAPEUTICS LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

ATH chart


Full chart

ATH upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪82.15 M‬ AUD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.004 AUD
Net income (FY)
‪−19.12 M‬ AUD
Revenue (FY)
0.00 AUD
Shares float
‪8.93 B‬
Beta (1Y)
2.79

Employees


Employees (FY)
10
Change (1Y)
−1 −9.09%
Revenue / Employee (1Y)
0.00 AUD
Net income / Employee (1Y)
‪−1.91 M‬ AUD

About ALTERITY THERAPEUTICS LIMITED


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David A. Stamler
Website
alteritytherapeutics.com
Headquarters
Melbourne
Founded
1997
ISIN
AU0000043945
FIGI
BBG000CDZM28
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

ATH news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as ATH.

Frequently Asked Questions


The current price of ATH is 0.007 AUD — it has decreased by −22.22% in the past 24 hours. Watch ALTERITY THERAPEUTICS LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on ASX exchange ALTERITY THERAPEUTICS LIMITED stocks are traded under the ticker ATH.
ATH stock has fallen by −12.50% compared to the previous week, the month change is a −30.00% fall, over the last year ALTERITY THERAPEUTICS LIMITED has showed a 40.00% increase.
We've gathered analysts' opinions on ALTERITY THERAPEUTICS LIMITED future price: according to them, ATH price has a max estimate of 0.08 AUD and a min estimate of 0.01 AUD. Watch ATH chart and read a more detailed ALTERITY THERAPEUTICS LIMITED stock forecast: see what analysts think of ALTERITY THERAPEUTICS LIMITED and suggest that you do with its stocks.
ATH reached its all-time high on Jul 1, 2020 with the price of 0.410 AUD, and its all-time low was 0.002 AUD and was reached on Aug 7, 2024. View more price dynamics on ATH chart.
See other stocks reaching their highest and lowest prices.
ATH stock is 28.57% volatile and has beta coefficient of 2.79. Track ALTERITY THERAPEUTICS LIMITED stock price on the chart and check out the list of the most volatile stocks — is ALTERITY THERAPEUTICS LIMITED there?
Today ALTERITY THERAPEUTICS LIMITED has the market capitalization of ‪82.15 M‬, it has increased by 14.29% over the last week.
Yes, you can track ALTERITY THERAPEUTICS LIMITED financials in yearly and quarterly reports right on TradingView.
ALTERITY THERAPEUTICS LIMITED is going to release the next earnings report on Aug 28, 2025. Keep track of upcoming events with our Earnings Calendar.
ATH earnings for the last half-year are −0.0014 AUD per share, whereas the estimation was −0.0017 AUD, resulting in a 18.22% surprise. The estimated earnings for the next half-year are −0.0014 AUD per share. See more details about ALTERITY THERAPEUTICS LIMITED earnings.
ALTERITY THERAPEUTICS LIMITED revenue for the last half-year amounts to ‪111.30 K‬ AUD, despite the estimated figure of ‪3.71 M‬ AUD. In the next half-year revenue is expected to reach ‪4.45 M‬ AUD.
ATH net income for the last half-year is ‪−7.17 M‬ AUD, while the previous report showed ‪−12.62 M‬ AUD of net income which accounts for 43.14% change. Track more ALTERITY THERAPEUTICS LIMITED financial stats to get the full picture.
No, ATH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 17, 2025, the company has 10 employees. See our rating of the largest employees — is ALTERITY THERAPEUTICS LIMITED on this list?
Like other stocks, ATH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ALTERITY THERAPEUTICS LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ALTERITY THERAPEUTICS LIMITED technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ALTERITY THERAPEUTICS LIMITED stock shows the sell signal. See more of ALTERITY THERAPEUTICS LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.